Hints and tips:
Related Special Reports
...Swiss company Roche acquired obesity drug developer Carmot Therapeutics for $3.1bn last month, while AstraZeneca signed a $2bn licensing agreement with Eccogene, a Chinese maker of an oral obesity drug in...
...This month, Roche agreed to buy Carmot Therapeutics, a US start-up with potential GLP-1 drugs, for up to $3.1bn....
...Roche is to acquire Carmot Therapeutics for up to $3.1bn, in the industry’s latest significant investment in the booming obesity treatment market....
...It is acquiring US-based obesity drugs developer Carmot Therapeutics for up to $3.1bn. It is the second bolt-on acquisition by Roche’s new chief executive Thomas Schinecker in less than two months....
...AstraZeneca has signed a licensing agreement with Chinese company Eccogene, which is developing a weight-loss pill, while Swiss pharma group Roche bought obesity drug developer Carmot Therapeutics for $2.7bn...
...Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing market for weight loss treatments...
...In December, BMS announced a $14bn deal for Karuna Therapeutics which owns the schizophrenia drug KarXT....
...Roche and AstraZeneca have already struck deals to buy or license early stage weight-loss drugs....
...Consider how Roche spent its cash. It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...California’s Carmot Therapeutics is working on GLP-1 and other analogues that promise to be relatively well-tolerated. Roche recently agreed to buy the company for up to $3bn....
...Arcus Biosciences soared 25 per cent and iTeos Therapeutics jumped 28 per cent in pre-market trading....
...Last month, Swiss pharmaceutical company Roche agreed an up to $3.1bn takeover of obesity drug developer Carmot Therapeutics....
...“Until it is further scrutinised, it is difficult to predict the value of this new antibiotic against serious Gram-negative infections as a singular therapeutic,” said Walsh, who was not involved in the...
...“The linkage of genomic and clinical data could enable researchers to develop novel therapeutics which can work in a more personalised way,” he added....
...The current poster child for venue abuse is the Sorrento Therapeutics case....
...One recent study found that fewer than a third of new drugs approved in Europe and the US between 2007 and 2017 were rated of “high therapeutic value”....
...Spring Metal — which Chourasia incorporated in the low-tax, high-secrecy Malaysian offshore centre of Labuan in January 2015, according to corporate records — is one of seven companies accused by Trafigura...
...Earlier this month, Amgen bought Horizon Therapeutics for $28bn....
...It has also narrowed its focus on two therapeutic areas: oncology and neurology....
...“The goal is actually to build an underlying platform which is . . . agnostic to those therapeutic areas,” he said....
...Franz Humer, former chair of Diageo and Roche, joined the board in March....
...The results are a boost for Roche’s Genentech. In 2016, it agreed to pay BioNTech a hefty $310mn to collaborate on its cancer programme....
...Roche does not make vaccines, although it makes a number of Covid-19 therapeutics, including Actemra, a rheumatoid arthritis drug that the World Health Organization recently recommended should be used in...
...Last year, it paid $1.5bn for Gyroscope Therapeutics, a company developing a potential treatment for blindness....
...The drug was developed by Regeneron/Roche and is administered either by injection or infusion, the statement said....
International Edition